Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update
Acasti Pharma, Inc. (ACST)
Last acasti pharma, inc. earnings: 2/14 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acastipharma.com/investors
Company Research
Source: GlobeNewswire
Surpassed 50% Enrollment Milestone in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104Company Anticipates Completion of Patient Enrollment in the STRIVE-ON Trial in Late 2024 to Early 2025, with NDA Submission on Track for 1H Calendar 2025Projected Cash Runway into Second Calendar Quarter 2026 PRINCETON, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced financial results and business highlights for the quarter ended June 30, 2024. “As a result of unrelenting focus on patient enrollment by the Acasti team and participating clinical trial sites, we surpassed the 50% enrollment milestone in our Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405),” said Prashant Kohli, CEO of Acasti. “Investigators contin
Show less
Read more
Impact Snapshot
Event Time:
ACST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACST alerts
High impacting Acasti Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
ACST
News
- Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. [Canadian Business Journal (Canada)]Canadian Business Journal
- Acasti Pharma changes name to Grace Therapeutics [Seeking Alpha]Seeking Alpha
- Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.GlobeNewswire
- Acasti Pharma Inc. (NASDAQ: ACST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Acasti Pharma Inc. (NASDAQ: ACST) had its price target raised by analysts at Craig Hallum from $6.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
ACST
Earnings
- 8/9/24 - Beat
ACST
Sec Filings
- 10/28/24 - Form 8-K
- 10/25/24 - Form 8-K
- 10/16/24 - Form EFFECT
- ACST's page on the SEC website